Literature DB >> 6991941

Metastatic adenocarcinomas of unknown primary site: a randomized study of two combination-chemotherapy regimens.

R L Woods, R M Fox, M H Tattersall, J A Levi, G N Brodie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6991941     DOI： 10.1056/NEJM198007103030205

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  11 in total

Review 1.  Carcinomas of an unknown primary origin--diagnosis and treatment.

Authors:  Christophe Massard; Yohann Loriot; Karim Fizazi
Journal:  Nat Rev Clin Oncol       Date:  2011-11-01       Impact factor: 66.675

2.  Gemcitabine and cisplatin in patients with carcinoma of unknown primary site.

Authors:  Metin Isik; Mehmet M Seker; Hatice Odabas; Fahriye T Kos; Dogan Uncu; Nurullah Zengin
Journal:  Med Oncol       Date:  2010-03-19       Impact factor: 3.064

3.  Carcinoma of Unknown Primary - an Orphan Disease?

Authors:  Alwin Krämer; Gerdt Hübner; Andreas Schneeweiss; Gunnar Folprecht; Kai Neben
Journal:  Breast Care (Basel)       Date:  2008-06-19       Impact factor: 2.860

4.  Adriamycin, vinblastine and mitomycin C as second-line chemotherapy in advanced breast cancer.

Authors:  A Sulkes; E Gez; M R Pfeffer; R Catane; R Isacson; S Biran
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

5.  Metastases in the Absence of a Primary Tumor: Advances in the Diagnosis and Treatment of CUP Syndrome.

Authors:  Kai Neben; Gerdt Hübner; Gunnar Folprecht; Dirk Jäger; Alwin Krämer
Journal:  Dtsch Arztebl Int       Date:  2008-10-24       Impact factor: 5.594

6.  Phase II study of combination 4'-epidoxorubicin and mitomycin C in recurrent epithelial ovarian cancer.

Authors:  C Redman; F Lawton; N Stuart; M O'Brien; J Buxton; J Mould; A Chetiyawardana; M Crawford; M Patterson; V Sykes
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

7.  The value of immunohistochemistry in patients with poorly differentiated adenocarcinomas and undifferentiated carcinomas of unknown primary.

Authors:  A van der Gaast; J Verwij; A S Planting; G Stoter; S C Henzen-Logmans
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

8.  Cost-effectiveness in the diagnosis and treatment of carcinoma of unknown primary origin.

Authors:  M N Levine; M F Drummond; R J Labelle
Journal:  CMAJ       Date:  1985-11-15       Impact factor: 8.262

9.  How should cancer presenting as a malignant pleural effusion be managed?

Authors:  H Bonnefoi; I E Smith
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

10.  Adenocarcinoma of unknown primary site.

Authors:  Seo Young Song; Won Seog Kim; Hye Ran Lee; Hyun Sik Jung; Sung Yong Oh; Ji Hyang Kim; Kihyun Kim; Eun Mi Nam; Young Ryun Oh; Chul Won Jung; Sung Soo Yoon; Young Hyuck Im; Hong Ghi Lee; Won Ki Kang; Chan Hyung Park; Keunchil Park
Journal:  Korean J Intern Med       Date:  2002-12       Impact factor: 2.884
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.